Molecular blueprint may unlock personalized liver cancer therapy

NCT ID NCT05516628

Recruiting now Knowledge-focused Sponsor: National Cancer Centre, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study investigates why some liver cancers respond to immunotherapy (atezolizumab plus bevacizumab) after surgery while others do not. Researchers will collect detailed molecular data from tumors and blood samples of 30 patients to find biomarkers that predict response, resistance, or recurrence. The goal is to pave the way for more personalized treatment decisions in liver cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab plus Bevacizumab
What this could lead to: If successful, this could help doctors choose the most effective treatment for each liver cancer patient, improving outcomes and reducing recurrence.
What could go wrong: This is a small, early-phase study focused on discovery, not treatment. The biomarkers identified may not prove useful in larger, diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Changi General Hospital
RECRUITING

Singapore, 529889, Singapore
National Cancer Centre Singapore
RECRUITING

Singapore, 169610, Singapore
National University Hospital Singapore
RECRUITING

Singapore, 119074, Singapore
Sengkang General Hospital
RECRUITING

Singapore, 544886, Singapore
Singapore General Hospital
RECRUITING

Singapore, 169856, Singapore
Tan Tock Seng Hospital
ACTIVE_NOT_RECRUITING

Singapore, 308433, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.